B
TRVI icon

Bailard’s Trevi Therapeutics TRVI Stock Holding History

Bailard’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,133
Closed -$117K – 837
2024
Q3 		$117K Sell
35,133
-5,767
-14% -$17.1K ﹤0.01% 726
2024
Q2 		$122K Hold
40,900
– – ﹤0.01% 707
2024
Q1 		$141K Buy
+40,900
New +$91.3K ﹤0.01% 714
2023
Q2 		– Sell
-21,200
Closed -$39.2K – 790
2023
Q1 		$39.2K Hold
21,200
– – ﹤0.01% 707
2022
Q4 		$40.9K Buy
+21,200
New +$41.8K ﹤0.01% 698

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Bailard's TRVI Position: Q4 2024 in Review

Bailard sold out of Trevi Therapeutics (TRVI) in Q4 2024, closing a stake of 35,133 shares — an estimated $117K sold.

Bailard first reported a position in TRVI in Q4 2022 and held it in 5 quarters. The position peaked at $141K in Q1 2024. 110 funds tracked by Wall St. Rank hold TRVI as of Q4 2024.

  • Bailard reported no remaining Trevi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Bailard sold 35,133 Trevi Therapeutics shares in Q4 2024, an estimated $117K.
  • Bailard first reported a position in Trevi Therapeutics in Q4 2022 and held it in 5 quarters.
  • Bailard's Trevi Therapeutics position peaked at $141K in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q4 2024.

Based on Bailard's 13F filing for Q4 2024, filed 5 Feb 2025.